UPDATE 1-SkyePharma says more tests needed for asthma drug

Tue Sep 1, 2009 3:44am EDT

* More clinical data needed by U.S. authorities

* Says U.S. approval of Flutiform 'unlikely' before H2 2011

* Partner Abbott will pay for tests and can recoup costs

* Shares fall almost 4 percent

(Adds details)

LONDON, Sept 1 (Reuters) - British drug delivery company SkyePharma (SKP.L) said on Tuesday it will need to do more tests on its asthma drug Flutiform, pushing the expected U.S. approval out to late 2011 and sending its shares down almost 4 percent.

The company has been told by the U.S. Food and Drug Administration that further tests will be required to get more data on the effects of different doses.

At 0731 GMT shares in the company were down almost 4 percent to nearly 107 pence per share.

Under the current license agreement, the company's development partner Abbott (ABT.N) is responsible for paying for additional U.S. clinical trials, and is entitled to recoup its costs from future milestones and royalties.

(Reporting by Ben Deighton; Editing by Clara Ferreira-Marques)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

California state worker Albert Jagow (L) goes over his retirement options with Calpers Retirement Program Specialist JeanAnn Kirkpatrick at the Calpers regional office in Sacramento, California October 21, 2009. Calpers, the largest U.S. public pension fund, manages retirement benefits for more than 1.6 million people, with assets comparable in value to the entire GDP of Israel. The Calpers investment portfolio had a historic drop in value, going from a peak of $250 billion in the fall of 2007 to $167 billion in March 2009, a loss of about a third during that period. It is now around $200 billion. REUTERS/Max Whittaker   (UNITED STATES) - RTXPWOZ

How to get out of debt

Financial adviser Eric Brotman offers strategies for cutting debt from student loans and elder care -- and how to avoid money woes in the first place.  Video